WO1988000210A1 - A process for producing a coagulation active complex of factor viii fragments - Google Patents
A process for producing a coagulation active complex of factor viii fragments Download PDFInfo
- Publication number
- WO1988000210A1 WO1988000210A1 PCT/DK1987/000080 DK8700080W WO8800210A1 WO 1988000210 A1 WO1988000210 A1 WO 1988000210A1 DK 8700080 W DK8700080 W DK 8700080W WO 8800210 A1 WO8800210 A1 WO 8800210A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fviii
- process according
- complex
- promoting agent
- units
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Definitions
- the present invention concerns a process for producing a coagulation active complex of an N terminal fragment of Factor VIII with a molecular weight of 92 to 210 kd and a C terminal fragment of Factor VIII with a molecular weight of 80 to 70 kd.
- Factor VIII is a protein occurring naturally in blood
- FVIII may be activated by thrombin or FXa and be inactivated by thrombin, FXa or protein C.
- Hemophilia A patients are treated with FVIII preparations, either prophy lact ically or acutely in case of bleedings.
- FVIII can be recovered from human blood plasma in which about 1 ppm of the protein is FVIII. This method can only produce limited amounts of FVIII, and it is therefore desirable to produce FVIII biosynthetically in cell culture. Three groups of researchers have been successful in doing this (Wood et al, Nature 312, p. 330, 1984 - Toole et al, Nature 312, p. 342, 1984 - Truet et al, DNA 4, p. 333, 1985).
- FVIII is a very large protein with a molecular weight of about 330 kd (Vehar et al, Nature 312, p. 337, 1984).
- FVIII purified from blood plasma or from cell culture comprises a fragment called Factor VIII light chain or FVIII-LC with a molecular weight of about 80 kd, and a fragment called FVIII heavy chain or FVIII-HC with a molecular weight of from 92 to 210 kd.
- the fragments are produced from the 330 kd protein by proteolytic cleavage so that 80 kd FVIII-LC is the C terminal fragment, while FVIII-HC is the N-terminal fragment whose size depends upon the degree of cleavage.
- coagulation active FVIII includes an 80 kd fragment and a fragment with a molecular weight of 92 kd or more (Fulcher and Zimmerman, Symposium on FVIII, Scripps Clinic, 1982).
- the present invention is based on the finding that a coagulation active complex is produced when a coagulation inactive FVIII-heavy chain (FVIII-HC, N-terminal fragment) is caused to react with a coagulation inactive FVIII-light chain (FVIII-LC, C-terminal fragment) in the presence of a complex promoting agent.
- FVIII-HC coagulation inactive FVIII-heavy chain
- FVIII-LC coagulation inactive FVIII-light chain
- FVIII-LC can be purified from human plasma and has no coagulation activity (see W0 86/02838).
- FVIII-HC fragments can also be purified from blood plasma (Truett et al, DNA 4, p. 333, 1985). Also these fragments are without coagulation activity.
- one or more divalent metal ions are preferably used as complex promoting agents. Examples of suitable agents of this type are Mn 2+ , Ca 2+ and Ca 2+ .
- Other suitable complex promoting agents are FIXa and FX and substances having reactivity to R-SH and/or R-S-S-R compounds. If desired, a mixture of these agents may be used.
- FVIII-LC or FVIII light chain is a fragment from the C terminal domain of full length FVIII.
- the molecular weight of the fragment is typically about 80 kd, but may be 70 kd or less.
- the fragment with the molecular weight of 80 kd has immunological reactivity in the described assay for FVIII-LC antigen and not in assay for FVIII-HC antigen.
- FVIII-HC or FVIII heavy chain is a fragment from the N terminal domain of full length FVIII.
- the molecular weight of the fragment is typically 92 kd, but may be less and up to 210 kd.
- FVIII-HC purified from plasma consists of a mixture with a molecular weight of 92 to 210 kd.
- the fragment with a molecular weight greater than or equal to 92 kd has immunological reactivity in the described assay for FVIII-HC antigen but not in assay for FVIII-LC antigen.
- Coagulation active FVIII is a protein which is capable of reducing the coagulation time of hemophilia A plasma in coagulation assay. Coagulation active FVIII is moreover capable of promoting the formation of FXa in Coatest assay (cf. the following) and thus of converting the chromogenic substrate. Coagulation activity is stated as FVIII.C.
- Prothrombin complex is coagulation factors containing ⁇ -carboxyglutamic acid, i.e. FII, FVII, FIX, FX protein C or activated forms of these coagulation factors (Davie et al, Advances in enzymology 48 p. 277, 1979).
- FVIII:C is measured in a system consisting of FIXa, FX, Ca 2+ and phospholipid (PL) (Rosen et al, Thromb Haemostas 54 p. 818, 1985).
- FXa is formed in an amount depending upon the amount of FVIII : C.
- the assay is performed as indicated be l ow :
- a 50 ⁇ l sample is mixed with 50 ⁇ l of activation reagent (mixture of FIXa/FX and PL). Incubation time 10 min., 22°C.
- FVIII-LC antigen Ag is measured In specific immuno- assay (Nordfang et al, Thromb Haemostas 53, p. 346, 1985). Human inhibitor antibody is coated to microplates, sample is added, and bound FVIII-LC is detected with peroxidase labelled F(ab') 2 fragment of human inhibitor IgG. Normal human plasma is used as a standard.
- FVIII-HC antigen (Ag) is measured in specific inhibition assay. Dog inhibitor antibody is coated to microplates with loose wells. Sample and 125 I-labelled FVIII-HC are added. The amount of FVIII-HC In the sample determines the amount of bound 125 I-FVIII-HC.
- the standard is FVIII concentrate (FVIII Nordisk) set to contain 1 FVIII-HC unit per FVIII:C unit.
- FVIII-LC and FVIII-HC determined by immuno- assay are stated relatively. That is the proportion between unit FVIII.C unit FVIII-LCAg unit FVIII-HCAg for various types of FVIII is not 1:1:1. However, it is assumed that units of the various assays are comparable, but there may be some difference between VIII:C unit, FVIII-LCAg unit and FVIII-HCAg unit for a FVIII sample in which all protein is coagulation active in coatest.
- FVIII sample for control tests was produced from FVIII concentrate (see WO 84/03628) by affinity chromatography on goat anti-von Willebrand Factor Sepharose (Truett et al, DNA 4 p. 333, 1985).
- FVIII-LC may be purified from blood plasma by several methods (as described e.g. in W0 86/02838). Here, highly concentrated FVIII-LC is used, isolated by affinity chromato:graphy on monoclonal 47 IgG of Nordiocto, produced as described by 0. Nordfang et al.: Thrombosis and Haemostasis, Vol. 54, p. 586-590, 1985.
- Nordiocto dissolved in 200 ml of buffer A (0.02 M imidazole, 0.15 M NaCl, 10 mM EDTA, pH 7.4) to a concentration of VIII-LCAg of 110 units/ml, was incubated overnight with 7 ml of 47 IgG sepharose (coupled with 9 mg of IgG/ml). The incubatidn mixture was poured on a column, and eluate was collected. The gel was washed with 40 ml of buffer A and 40 ml of buffer A with a total of 0.65 M NaCl.
- FVIII-LC was eluted with 40 ml of 20 mM imidazole/0.65 M NaCl/10 mM EDTA/50% ethylene glycol/pH 7.4.
- a peak fraction of 4 ml was dialysed to 50 mM imidazole/0.15 M NaCl/10% glycerol/0.02% NaN 3 ,/pH 7.4.
- the content of FVIII components in the dialysed sample appears from table 1.
- FVIII-HC is produced from a FVIII sample by affinity chromatography on monoclonal 56 IgG Sepharose (produced as stated by 0. Nordfang et al.: Thrombosis and Haemostasis, Vol. 54, p. 586-590, 1985.
- 56 IgG Sepharose binds the F VI I I-LC/F V 111-HC complex via FVIII-LC.
- 25 ml of FVIII sample with a content o-f 405 FVIII-HCAg units/ml were incubated overnight with 1.5 ml of 56 IgG Sepharose (coupled with 4 mg of 56 IgG/ml). The incubation mixture was poured on a column, and eluate was collected.
- the gel was washed with 5 ml of buffer B (20 mM imidazole/0.15 M NaCl/10% glycerol/0.1 M lysine/pH 7.4) containing 0.35 M CaCl 2 . Then the gel was washed with 15 ml of buffer B with a total NaCl content of 0.65 M followed by 5 ml of buffer B with 10 mM EDTA and 0.0258 NaN (EDTA buffer). The gel was drained and incubated for 1 hour at room temperature with EDTA buffer. After Incubation, FVIII-HC was eluted with 5 ml of EDTA buffer.
- Lane 1 corresponds to sample A (FVIII-LC) 4 FVIII-LCAg units
- Lane 2 contains molecular weight markers, and Lane 3 corresponds to sample B (FVIII-HC) 8 FVIII-HCAg units.
- Samples A and B were each diluted 10 times in buffer C (50 mM imidazole, 0.15 M NaCl, 0.18 BSA, pH 7.4). 20 ⁇ l of A (diluted 1:10) was mixed with 20 ⁇ l of B
- Sample A was diluted 40 times in buffer C. 80 ⁇ l of A (diluted 1:40) were mixed with 3 ⁇ l of 0.15 M MnCl 2 . After 48 hours' incubation, the incubation mixture contained less than 5 units of VIII:C/ml. Similarly, an incubation mixture with sample B contained less than 5 m units of VIII:C/ml.
- FVIII sample diluted 1000 times in buffer C were mixed with 3 ⁇ l of 0.15 M MnCl 2 . After 48 hours' incubation 170 m units of VIII:C/ml were measured. 80 ⁇ l of FVIII sample diluted 1000 times in buffer C were mixed with 3 ⁇ l of buffer C. After 48 hours' incubation 140 m units of FVIII:C/ml were measured.
- Samples A and B were each diluted 10 times in buffer C. 20 ⁇ l of A 1:10 were mixed with 20 ⁇ l of B (diluted 1/10), 3 ⁇ l of 2.2 M CaCl 2 and 40 ⁇ l of buffer C. After 12 days' incubation at 22°C, the incubation mixture contained 1300 m units of VIII:C/ml.
- Samples A and B were each diluted 100 times in buffer C. 100 ⁇ l of A and 100 ⁇ l of B were mixed. 50 ⁇ l of the mixture were tested in Coatest, as described above. 1.5 m units/ml were measured in the mixture. 50 ⁇ l of the mixture were moreover tested in modified Coatest with 1 hour's preincubation with FIXa/FX prior to addition of PL. Hereby, the Coatest activity increased to 3.0 m units/ml.
- FVIII sample was diluted 30,000 times in buffer C. 50 ⁇ l of diluted sample were tested in Coatest, as described above. 3.4 m units/ml were measured. 50 ⁇ l of the diluted FVIII sample were moreover tested in modified Coatest with 1 hour's preincubation with FIXa/FX prior to addition of PL. 3.8 m units/ml were measured for the diluted FVIII sample.
- the experiment was performed as described in example 1, first comparison experiment. After 24 hours' incubation less than 5 m units/ml were measured in the incubation mixture.
- Samples A and B were each diluted 20 times in buffer C. 20 ⁇ l A 1/20 were mixed with 20 ⁇ l B 1/20, 40 ⁇ l FIXa/FX and 3 ⁇ l 0.15M CaCl 2 . After 4 hours' incubation at 22°C the incubation mixture contained 199 mil of
- FVIII:C/ml If FIXa/FX In the mixture was replaced by 40 ⁇ l buffer C, then 43 mU of FVIII:C/ml were measured after 4 hours' incubation
- mixture A contained 10.3 units of FVIII:C/ml
- mixture B contained 4.0 units
- mixture C contained 12.9 units of FVIII:C/ml.
- mixtures A, B and C contained 6.6 units, 6.5 units and 11.9 units of FVIII:C/ml, respectively.
- COS cells were transfected with plasmid pSVF8-80 which expresses 80 kD chain, cf. DK Patent Application 0428/87.
- Supernatant from the culture containing 870 m units of FVIII-LC : Ag/ml was supplemented with plasma-purified FVIII-HC to a final concentration of 20 FVIII-HC:Ag units/ml and Mn 2+ to a final concentration of 5 mM. After 24 hours' Incubation at 22°C the mixture contained 137 m units of FVIII:C/ml.
- FVIII-LC 25 ⁇ l of FVIII-LC were mixed in buffer C with 25 ⁇ l of FVIII-HC, 7 ⁇ l of MnCl 2 and 10 ⁇ l of redox agent to obtain end concentrations of the individual components as stated in table 2.
- FVIIIrC was measured after 5 hours' incubation at 20oC.
- FVIII-HC was produced as described above and with the modification that EDTA el'ution buffer and dialysis buffer were mixed with 50 ⁇ m of mereapto ethanol. After dilution recombination with FVIII-HC samples was performed with 20 hours' incubation in buffer C at room temperature with addition of mercapto ethanol to 35 ⁇ M, MnCl 2 to 5 mM and FVIII-LC to 22 FVIII-LC:Ag units/ml.
- Table 3 shows recombination with the two FVIII-HC sample types.
- FVIII:C units/ml were measured. In a corresponding incubation mixture without FX, 0.59 FVIII.C unit/ml was measured after 20 hours' incubation at 20°C.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Compounds Of Unknown Constitution (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE3788944T DE3788944T2 (en) | 1986-06-24 | 1987-06-24 | METHOD FOR PRODUCING A COAGULATION-ACTIVE COMPLEX FROM FACTOR VIII FRAGMENT. |
AT87904383T ATE100825T1 (en) | 1986-06-24 | 1987-06-24 | PROCEDURE FOR PREPARING A COAGULATION-ACTIVE COMPLEX FROM FACTOR VIII FRAGMENT. |
NO880776A NO176244C (en) | 1986-06-24 | 1988-02-23 | Process for preparing a coagulation-active complex of Factor VIII fragments |
DK092188A DK163833C (en) | 1986-06-24 | 1988-02-23 | PROCEDURE FOR THE PREPARATION OF A COAGULATION-ACTIVE COMPLEX OF FACTOR VIII FRAGMENTS |
FI880852A FI100107B (en) | 1986-06-24 | 1988-02-23 | A method for preparing a combination of coagulation enhancing factor VIII fragments |
US08/383,034 US5610278A (en) | 1986-06-24 | 1995-02-03 | Process for producing a coagulation active complex of factor VIII fragments |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK2957/86 | 1986-06-24 | ||
DK295786A DK295786A (en) | 1986-06-24 | 1986-06-24 | PROCEDURE FOR PREPARING A COAGULATION-ACTIVE COMPLEX OF FACTOR VIII FRAGMENTS |
CA000559223A CA1305413C (en) | 1986-06-24 | 1988-02-18 | Process for producing a coagulation active complex of factor viii fragments |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1988000210A1 true WO1988000210A1 (en) | 1988-01-14 |
Family
ID=25671724
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DK1987/000080 WO1988000210A1 (en) | 1986-06-24 | 1987-06-24 | A process for producing a coagulation active complex of factor viii fragments |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0272304B1 (en) |
JP (1) | JP2593500B2 (en) |
AU (1) | AU607927B2 (en) |
CA (1) | CA1305413C (en) |
DE (1) | DE3788944T2 (en) |
NO (1) | NO176244C (en) |
WO (1) | WO1988000210A1 (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0275305A1 (en) * | 1986-08-01 | 1988-07-27 | Inc. Biogen | Dna sequences coding for modified factor viii:c and modified factor viii:c-like polypeptides and processes for producing these polypeptides in high yields |
US5198349A (en) * | 1986-01-03 | 1993-03-30 | Genetics Institute, Inc. | Method for producing factor VIII:C and analogs |
US5296467A (en) * | 1989-07-15 | 1994-03-22 | Boehringer Ingelheim International Gmbh | Composition comprising an anticoagulant |
WO1995018827A1 (en) * | 1994-01-07 | 1995-07-13 | Novo Nordisk A/S | Factor viii derivatives |
US5627038A (en) * | 1989-08-17 | 1997-05-06 | Dade International Inc. | Factor IX chromogenic assay |
US6599724B1 (en) | 1999-07-13 | 2003-07-29 | Biovitrum Ab | Stable factor VIII compositions |
WO2004103397A1 (en) * | 2003-05-19 | 2004-12-02 | National Institute For Biological Standards And Control (Nibsc) | Compositions comprising factor viii and factor ixa for treating haemophilia |
US7790852B2 (en) | 2003-06-25 | 2010-09-07 | Novo Nordisk Health Care A/G | Liquid composition of factor VII polypeptides |
US7897734B2 (en) | 2003-03-26 | 2011-03-01 | Novo Nordisk Healthcare Ag | Method for the production of proteins |
US8022031B2 (en) | 2001-12-21 | 2011-09-20 | Novo Nordisk Health Care A/G | Liquid composition of factor VII polypeptides |
US8026214B2 (en) | 2003-08-14 | 2011-09-27 | Novo Nordisk Health Care Ag | Liquid, aqueous pharmaceutical compositions of factor VII polypeptides |
US8299029B2 (en) | 2002-06-21 | 2012-10-30 | Novo Nordisk Health Care Ag | Stabilised solid compositions of factor VII polypeptides |
US8536127B2 (en) | 2003-05-23 | 2013-09-17 | Novo Nordisk Healthcare Ag | Protein stabilization in solution |
US8658597B2 (en) | 2003-12-19 | 2014-02-25 | Novo Nordisk Healthcare Ag | Stabilised compositions of factor VII polypeptides |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0123945A1 (en) * | 1983-03-31 | 1984-11-07 | The Scripps Research Institute | New factor VIII coagulant polypeptides |
EP0182372A2 (en) * | 1984-11-21 | 1986-05-28 | Scripps Clinic And Research Foundation | New factor VIII coagulant polypeptides |
EP0197901A1 (en) * | 1985-03-05 | 1986-10-15 | Pharmacia AB (reg.number 556131-9608) | Biologically active fragments of the human antihemophilic factor and method for their preparation and pharmaceutical preparations |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0826078B2 (en) * | 1984-01-12 | 1996-03-13 | カイロン コーポレイション | Factor-V III C composition |
-
1987
- 1987-06-24 DE DE3788944T patent/DE3788944T2/en not_active Expired - Fee Related
- 1987-06-24 WO PCT/DK1987/000080 patent/WO1988000210A1/en active IP Right Grant
- 1987-06-24 JP JP62504030A patent/JP2593500B2/en not_active Expired - Fee Related
- 1987-06-24 AU AU76448/87A patent/AU607927B2/en not_active Ceased
- 1987-06-24 EP EP87904383A patent/EP0272304B1/en not_active Expired - Lifetime
-
1988
- 1988-02-18 CA CA000559223A patent/CA1305413C/en not_active Expired - Fee Related
- 1988-02-23 NO NO880776A patent/NO176244C/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0123945A1 (en) * | 1983-03-31 | 1984-11-07 | The Scripps Research Institute | New factor VIII coagulant polypeptides |
EP0182372A2 (en) * | 1984-11-21 | 1986-05-28 | Scripps Clinic And Research Foundation | New factor VIII coagulant polypeptides |
EP0197901A1 (en) * | 1985-03-05 | 1986-10-15 | Pharmacia AB (reg.number 556131-9608) | Biologically active fragments of the human antihemophilic factor and method for their preparation and pharmaceutical preparations |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5198349A (en) * | 1986-01-03 | 1993-03-30 | Genetics Institute, Inc. | Method for producing factor VIII:C and analogs |
EP0275305A1 (en) * | 1986-08-01 | 1988-07-27 | Inc. Biogen | Dna sequences coding for modified factor viii:c and modified factor viii:c-like polypeptides and processes for producing these polypeptides in high yields |
EP0275305A4 (en) * | 1986-08-01 | 1988-11-07 | Biogen Nv | Dna sequences coding for modified factor viii:c and modified factor viii:c-like polypeptides and processes for producing these polypeptides in high yields. |
US5296467A (en) * | 1989-07-15 | 1994-03-22 | Boehringer Ingelheim International Gmbh | Composition comprising an anticoagulant |
US5627038A (en) * | 1989-08-17 | 1997-05-06 | Dade International Inc. | Factor IX chromogenic assay |
WO1995018827A1 (en) * | 1994-01-07 | 1995-07-13 | Novo Nordisk A/S | Factor viii derivatives |
US6599724B1 (en) | 1999-07-13 | 2003-07-29 | Biovitrum Ab | Stable factor VIII compositions |
US8461116B2 (en) | 2001-12-21 | 2013-06-11 | Novo Nordisk Healthcare Ag | Liquid composition of factor VII polypeptides |
US8022031B2 (en) | 2001-12-21 | 2011-09-20 | Novo Nordisk Health Care A/G | Liquid composition of factor VII polypeptides |
US8729022B2 (en) | 2002-06-21 | 2014-05-20 | Novo Nordisk Healthcare Ag | Stabilised solid compositions of factor VII polypeptides |
US8299029B2 (en) | 2002-06-21 | 2012-10-30 | Novo Nordisk Health Care Ag | Stabilised solid compositions of factor VII polypeptides |
US7897734B2 (en) | 2003-03-26 | 2011-03-01 | Novo Nordisk Healthcare Ag | Method for the production of proteins |
US8084587B2 (en) | 2003-03-26 | 2011-12-27 | Novo Nordisk Health Care Ag | Method for the production of proteins |
US7977460B2 (en) | 2003-05-19 | 2011-07-12 | National Institute For Biological Standards And Control | Compositions comprising coagulation factors IXA and VIII for the treatment of haemophilia A or B |
WO2004103397A1 (en) * | 2003-05-19 | 2004-12-02 | National Institute For Biological Standards And Control (Nibsc) | Compositions comprising factor viii and factor ixa for treating haemophilia |
US8536127B2 (en) | 2003-05-23 | 2013-09-17 | Novo Nordisk Healthcare Ag | Protein stabilization in solution |
US7790852B2 (en) | 2003-06-25 | 2010-09-07 | Novo Nordisk Health Care A/G | Liquid composition of factor VII polypeptides |
US8026214B2 (en) | 2003-08-14 | 2011-09-27 | Novo Nordisk Health Care Ag | Liquid, aqueous pharmaceutical compositions of factor VII polypeptides |
US8318904B2 (en) | 2003-08-14 | 2012-11-27 | Novo Nordisk Health Care Ag | Liquid, aqueous pharmaceutical compositions of factor VII polypeptides |
US8658597B2 (en) | 2003-12-19 | 2014-02-25 | Novo Nordisk Healthcare Ag | Stabilised compositions of factor VII polypeptides |
Also Published As
Publication number | Publication date |
---|---|
NO176244B (en) | 1994-11-21 |
AU7644887A (en) | 1988-01-29 |
NO176244C (en) | 1995-03-01 |
NO880776D0 (en) | 1988-02-23 |
EP0272304B1 (en) | 1994-01-26 |
CA1305413C (en) | 1992-07-21 |
DE3788944D1 (en) | 1994-03-10 |
EP0272304A1 (en) | 1988-06-29 |
JP2593500B2 (en) | 1997-03-26 |
AU607927B2 (en) | 1991-03-21 |
DE3788944T2 (en) | 1994-05-26 |
NO880776L (en) | 1988-04-22 |
JPH01500514A (en) | 1989-02-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5543502A (en) | Process for producing a coagulation active complex of factor VIII fragments | |
AU607927B2 (en) | A process for producing a coagulation active complex of factor viii fragments | |
Sandberg et al. | Structural and functional characteristics of the B-domain-deleted recombinant factor VIII protein, r-VIII SQ | |
Kornalik et al. | Prothrombin activation induced by Ecarin-a prothrombin converting enzyme from Echis carinatus venom | |
EP0197901B1 (en) | Biologically active fragments of the human antihemophilic factor and method for their preparation and pharmaceutical preparations | |
Lollar et al. | Stabilization of thrombin-activated porcine factor VIII: C by factor IXa phospholipid | |
Rosing et al. | Coagulation factor V: an old star shines again | |
Richter et al. | Activation and inactivation of human factor X by proteases derived from Ficus carica | |
Clarke et al. | The short loop between epidermal growth factor-like domains 4 and 5 is critical for human thrombomodulin function. | |
EP0182372A2 (en) | New factor VIII coagulant polypeptides | |
KR100457984B1 (en) | Methods of Purification of Factor VII and Activated Factor VII | |
DEGUCHI et al. | Prothrombin kringle 1 domain interacts with factor Va during the assembly of prothrombinase complex | |
Egeberg | On the natural blood coagulation inhibitor system investigations of inhibitor factors based on antithrombin deficient blood | |
Lapan et al. | Interaction of the A1 subunit of factor VIIIa and the serine protease domain of factor X identified by zero-length cross-linking | |
Lyttleton | The antithrombin activity of heparin | |
Nordenman et al. | Purification of thrombin by affinity chromatography on immobilized heparin | |
US6034222A (en) | Method for the separation of recombinant pro-factor IX from recombinant factor IX | |
Fischer et al. | Biochemical and functional characterization of recombinant von Willebrand factor produced on a large scale | |
Hessel et al. | Fibrinogen Aarhus—a new case of dysfibrinogenemia | |
BORGEL et al. | Implication of protein S thrombin-sensitive region with membrane binding via conformational changes in the γ-carboxyglutamic acid-rich domain | |
Seegers et al. | Preparation of bovine prethrombin 2: Use of acutin and activation with prothrombinase or ecarin | |
JP2677546B2 (en) | Factor VIII fragment complex coagulation activator | |
Vermeer et al. | A new method for the preparation of artificial factor II reagents from normal human and bovine plasma | |
JP2593500C (en) | ||
Dode et al. | Characterization of a proteolytically modified form of human prothrombin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU DK FI JP NO US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1987904383 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 880852 Country of ref document: FI |
|
WWP | Wipo information: published in national office |
Ref document number: 1987904383 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1987904383 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 880852 Country of ref document: FI |